


SICKLE CELL CAUSE CIC Company Number: 15037726 (England and Wales)

Dormant Company Accounts / Unaudited Financial Statements

for

the Year Ended 31 July 2024



Sickle Cell Cause CIC (Registered number: 15037726)

Contents of the Financial Statements

for the Year Ended 31 July 2024

Page

Company Information 1

Balance Sheet 2

Statements 3

Notes to the Financial Statements 4

Sickle Cell Cause CIC

**Company Information
for the Year Ended 31 July 2024**

DIRECTOR:

L C Palmer

REGISTERED OFFICE:

23 Connaught Road

London

N4 4NT

Accountant

-

REGISTERED NUMBER: 15037726 (England and Wales)

Sickle Cell Cause

Balance Sheet

As of July 31, 2024

	TOTAL
Fixed Asset	
Total Fixed Asset	
Cash at bank and in hand	
SC.CAUSE	625.81
Total Cash at bank and in hand	£625.81
NET CURRENT ASSETS	£625.81
NET CURRENT ASSETS (LIABILITIES)	£625.81
TOTAL ASSETS LESS CURRENT LIABILITIES	£625.81
TOTAL NET ASSETS (LIABILITIES)	£625.81
Capital and Reserves	
Opening Balance Equity	100.00
Retained Earnings	9.60
Profit for the year	516.21
Total Capital and Reserves	£625.81

Sickle Cell Cause CIC
for the Year Ended 31 July 2024

Statements

For the financial year ending 31 July 2024, the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to:


- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006; and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year in accordance with Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

In accordance with Section 444 of the Companies Act 2006, the profit and loss account has not been delivered to the Registrar of Companies.

The financial statements were approved by the board of directors and authorised for issue on 28 April 2025 and were signed on its behalf by:

Signed:



Leanne Palmer
Director

Sickle Cell Cause CIC

Notes to the Financial Statements for the year ended 31 July 2024

1. Statutory Information

Sickle Cell Cause CIC is a Community Interest Company registered in England and Wales.
Company number: 15037726.

Registered office:
23 Connaught Road
London
N4 4NT

2. Accounting Policies

Basis of preparing the financial statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 105 (FRS 105) "The Financial Reporting Standard applicable to the Micro-entities Regime" and the Companies Act 2006.

3. Employees and Directors

The average number of employees during the year was nil.

4. Creditors: Amounts Falling Due Within One Year

There were no creditors falling due within one year as at 31 July 2024.

Important Notes:

This set of accounts is prepared for filing purposes only and does not include a profit and loss account.

These are "filleted" accounts for the Registrar of Companies and members.

Submission Address:

Companies House
Crown Way
Cardiff
CF14 3UZ

P/O- 23421337-15

CIC 34

Community Interest Company Report

*Please
complete in
typescript, or
in bold black
capitals.*

**Company Name in
full**

SICKLE CELL CAUSE CIC

Company Number

15037726

Year Ending

31st July 2024

*(The date format is required in full and should match
the date of the accounts e.g. 31st March 2020)*

Please ensure the company name is consistent with the company name entered on the accounts.

This template illustrates what the Regulator of Community Interest Companies considers to be best practice for completing a simplified community interest company report. All such reports must be delivered in accordance with section 34 of the Companies (Audit, Investigations and Community Enterprise) Act 2004 and contain the information required by Part 7 of the Community Interest Company Regulations 2005.

(N.B. A Filing Fee of £15 is payable on this document. Please enclose a cheque or postal order payable to Companies House)

PART 1 - GENERAL DESCRIPTION OF THE COMPANY'S ACTIVITIES AND IMPACT

In the space provided below, please insert a general account of the company's activities in the financial year to which the report relates, including a description of how they have benefited the community.

In the financial year ending [31st July 2024], Sickie Cell Cause CIC has continued its commitment to supporting individuals and families affected by sickle cell disorder (SCD) across the UK. Our activities have focused on education, advocacy, and community engagement to alleviate the challenges faced by those living with SCD.

Key Activities:

Educational Outreach: We conducted a series of workshops and seminars, in community centres, and healthcare settings to raise awareness about SCD, its symptoms, and management strategies. These sessions empowered attendees with knowledge to better understand and support those affected.

Support Services: Recognising the emotional and psychological toll of SCD, we established support groups providing a safe space for individuals and families to share experiences and coping mechanisms.

Advocacy Efforts: We engaged with policymakers and healthcare providers to advocate for improved services and resources for the SCD community. Our efforts contributed to increased visibility of the condition and the challenges faced by patients.

Community Events: Organised events during Sickie Cell Awareness Month to foster community solidarity and disseminate information about recent advancements in SCD treatment and care.

Impact on the Community: Our initiatives have led to heightened awareness of SCD, reduced stigma, and improved access to support services for affected individuals. Feedback indicates that participants in our programmes feel more informed and supported, contributing to better health outcomes and quality of life.

(If applicable, please just state "A social audit report covering these points is attached").

(Please continue on separate continuation sheet if necessary.)

PART 2 – CONSULTATION WITH STAKEHOLDERS – A “stakeholder” is any person or organisation affected by the company’s activities. Please indicate who the company’s stakeholders are; how the stakeholders have been consulted and what action has the company taken in response to feedback from its consultations. If there has been no consultation you must state ‘There has been no stakeholder consultation held’.

Sickle Cell Cause CIC recognises the importance of engaging with stakeholders to ensure our services effectively address the needs of those affected by sickle cell disorder (SCD). Our stakeholders include:

Individuals living with SCD and their families
Healthcare professionals and service providers
Educational institutions
Community organisations and support groups
Policy makers and health authorities

Consultation Methods:

Throughout the reporting period, we employed various methods to consult with our stakeholders:

Surveys and Feedback Forms: Distributed during workshops and events to gather insights on the effectiveness of our programmes and identify areas for improvement.

Focus Group Discussions: Conducted with patients and families to understand their experiences and needs, particularly concerning healthcare access and support services.

Stakeholder Meetings: Regular meetings with healthcare professionals and community leaders to discuss collaborative approaches to SCD awareness and care.

Online Platforms: Utilised social media and our website to solicit feedback and engage with a broader audience.

Actions Taken in Response to Feedback:

Feedback from our stakeholders has been instrumental in shaping our activities:

Enhanced Educational Materials: Based on suggestions, we updated our informational resources to be more accessible and culturally sensitive.

Expanded Support Services: In response to requests, we initiated additional support groups, including virtual sessions to accommodate those unable to attend in person.

Advocacy Efforts: Stakeholder input highlighted the need for improved healthcare services, leading us to engage more actively with policy makers to advocate for better SCD care provisions.

We remain committed to on-going dialogue with our stakeholders to ensure our services continue to meet the evolving needs of the SCD community

(If applicable, please just state “A social audit report covering these points is attached”).

PART 3 – DIRECTORS’ REMUNERATION – Please indicate below any remuneration the directors have received. Alternatively if you have provided full details in your accounts then you do not need to disclose it here but you must explain in the space below where they are found within the accounts. If no remuneration was received you must state that “no remuneration was received by the directors” below.

No remuneration was received by the directors.

PART 4 – TRANSFERS OF ASSETS OTHER THAN FOR FULL CONSIDERATION – Please insert full details of any transfers of assets other than for full consideration to an asset locked body or for the benefit of the community. This must include the amount, or contain a fair estimate of the value, of such transfer. If this does not apply you must state that “no transfer of assets other than for full consideration has been made” below.

No transfer of assets other than for full consideration has been made

(Please continue on separate continuation sheet if necessary.)

PART 5 – SIGNATORY

The original report must be signed by a director of the company

Signed



Date

28.04.2025

Please note that it is a legal requirement for the date format to be provided in full throughout the CIC34 report.

Applications will be rejected if this information is incorrect.

You do not have to give any contact information in the box opposite but if you do, it will help the Registrar of Companies to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record.

Email:	Tel:
DX Number	DX Exchange

When you have completed the form, please attach it to the accounts and send both documents to the Registrar of Companies at:

For companies registered in England, Scotland, Wales and Northern Ireland:

Companies House, Crown Way, Cardiff, CF14 3UZ

DX 33050 Cardiff

Please ensure the company name is consistent with the company name entered on the accounts. (N.B. Please enclose a cheque for £15 payable to Companies House).